Pricing & Sizes
Ships sealed and lyophilized — stable for years at room temperature, supplied as lyophilised powder. Free shipping on every order, no minimum. Every batch ships with its lab report. Reports come from third-party labs including Janoshik, Freedom Diagnostics and Chromate, most verifiable through the lab's own public portal. Ask and we will send the report for your batch.
Reconstitution — bacteriostatic water: 10mg vial reconstituted at 2mL gives 5mg/mL; 30mg vial reconstituted at 2mL gives 15mg/mL; 60mg vial reconstituted at 3mL gives 20mg/mL. These are concentrations, calculated from vial content and diluent volume. They describe the solution, not a dose.
Email To OrderIn Plain English
Tirzepatide activates two gut hormone receptors at once. GLP-1 reduces appetite and slows stomach emptying; GIP appears to improve how well GLP-1 works and helps with how the body handles fat and glucose. Hitting both is why it outperformed the single-target drugs that came before it, and the trial results behind that claim are real, large, and published.
What people use it for. Weight loss and blood sugar control. Alongside retatrutide, it is the most effective option in the metabolic category.
What to know before you buy. The clinical evidence here is genuinely excellent — large, randomised, published trials, not case reports. The complication is legal rather than scientific. During the 2022-2024 shortage, compounding pharmacies could lawfully make copies of tirzepatide. FDA declared that shortage over in December 2024, which removed that basis. Anyone buying or selling compounded tirzepatide should understand that the ground shifted. The gastrointestinal profile in the trials mirrors retatrutide.
What It's Studied For
| Research area | What that rests on |
|---|---|
| Body weight in trials | SURMOUNT-1 reported ~20.9% mean weight reduction at 72 weeks — large, randomised, placebo-controlled and published |
| Glucose regulation | Glucose handling was the primary endpoint across the SURPASS trial programme |
| Appetite signalling | GLP-1 receptor activation slows gastric emptying and reduces appetite |
| Dual mechanism | Adding GIP is why it outperformed the single-target drugs before it |
The left column lists the research areas this compound is investigated in; the right column states what that rests on. These are published research findings, not proven outcomes or treatment claims, and nothing here is a recommendation. Sold for laboratory research use only.
At a Glance
- Class
- Dual agonist at GIP and GLP-1 receptors
- FDA status
- Approved — as Mounjaro for type 2 diabetes and Zepbound for chronic weight management
- Trial evidence
- SURMOUNT-1 reported mean weight reduction of approximately 20.9% at 72 weeks on the highest dose in adults with obesity
- Compounding
- FDA declared the tirzepatide shortage resolved in December 2024, which ended the shortage-based basis for compounding copies under 503A and 503B
- Practical meaning
- Compounded tirzepatide no longer has the legal footing it had during the shortage period. This is separate from, and unaffected by, the July 2026 PCAC process
- Format
- 10mg, 30mg, and 60mg vials
Regulatory status — this one is different
Tirzepatide is an FDA-approved drug, sold as Mounjaro and Zepbound. Because an approved product exists, the rules governing compounded versions are different from every other compound in this range. During the 2022-2024 shortage, compounders could lawfully prepare copies; FDA declared that shortage resolved in December 2024, removing that basis. Compounded tirzepatide is therefore in a materially different and more exposed position than it was, and this has nothing to do with the July 2026 PCAC hearing, which did not consider tirzepatide.
What the Trials Show
This is one of the few compounds here where the evidence is unambiguous. Two large trial programmes ran on it: SURPASS, where the primary endpoints were glycaemic, and SURMOUNT, where they were body weight. SURMOUNT-1 reported roughly 20.9% mean weight reduction at 72 weeks on the top dose — figures that came from large, randomised, placebo-controlled trials with published results, not case series. Those are Lilly’s trials of their own approved product, and they describe the compound rather than anything sold here.
Adverse events were predominantly gastrointestinal and dose-related: nausea, diarrhoea, vomiting, and constipation, concentrated during dose escalation. The gradual escalation used in the published trials exists specifically to manage this.
What Research-Grade Material Is and Is Not
The trial results above were produced with the approved pharmaceutical product, manufactured under cGMP with full identity, purity, and potency controls and dispensed with prescribing information. Research-grade tirzepatide is not that product and inherits none of those controls. The efficacy data belongs to the approved drug; it does not automatically transfer to material from an unregulated supply chain.
This distinction matters more for tirzepatide than for the unapproved compounds in this range, precisely because an approved comparator exists and the gap between the two is measurable.
The bottom line
The strongest efficacy evidence in this range by a wide margin, attached to the most complicated legal position. The science is settled; the compounding pathway narrowed considerably when FDA declared the shortage resolved in December 2024. Anyone buying or selling this should understand that change.
Also in the Range
Compare with Retatrutide, which reported larger reductions in phase II and adds a third receptor target, but has not completed phase III and is not approved anywhere.